SCHEMBL6556893

SCHEMBL6556893

C=C(COc1ccc(CCNC(=O)[C@@H](NS(=O)(=O)CC)C(C)C)cc1OC)c1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.52
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 5/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
ALDH1A1 P00352 3/20 0.47
CNR1 P21554 1/20 0.46
CTSD P07339 1/20 0.44
POLB P06746 1/20 0.43
TP53 P04637 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
THRB P10828 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7157119 0.92 GAA (0.52) GAAKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6554732 0.90 MEN1 (0.53) GAAKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6554726 0.90 MEN1 (0.53) GAAKMT2AMEN1LMNASMN1; SMN2
SCHEMBL13350353 0.88 KMT2A (0.51) GAAKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6555032 0.86 KMT2A (0.50) GAAKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6555027 0.86 KMT2A (0.50) GAAKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6553296 0.85 KMT2A (0.51) GAAKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6553298 0.85 KMT2A (0.51) GAAKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6553290 0.85 KMT2A (0.51) GAAKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6554764 0.84 SMN1; SMN2 (0.46) KMT2AMEN1LMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1135368-B1 ALPHA-SULFIN- AND ALPHA-SULFON-AMINO ACID AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2004-02-25 EP disclosed
US-6538016-B2 For controlling and preventing an infestation of crop plants by phytopathogenic microorganisms, preferably fungi SYNGENTA PARTICIPATIONS AG (CH) 2003-03-25 US disclosed
US-20020082452-A1 alpha-sulfin-and alpha-sulfonamino acid amides SYNGENTA PARTICIPATIONS AG (CH) 2002-06-27 US disclosed
EP-1135368-A2 ALPHA-SULFIN- AND ALPHA-SULFON-AMINO ACID AMIDES Syngenta Participations AG (CH) 2001-09-26 EP disclosed
WO-2000032568-A2 $G(A)-SULFIN- AND $G(A)-SULFONAMINO ACID AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2000-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082452-A1 alpha-sulfin-and alpha-sulfonamino acid amides SULT1A1, CBR1, SULT2A1 GAA 2769/4885KMT2A 2647/4885MEN1 3649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.